Physician profile
Marshall W Winner
NPI 1629190467
$55,606.43
in general payments reported to CMS, 2019-2025
26 companies · $7,170 in 2025
The $7,170 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,775 · 2020: $5,361 · 2021: $4,004 · 2022: $14K · 2023: $7,795 · 2024: $7,024 · 2025: $7,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,563 · Travel and Lodging: $7,584 · Food and Beverage: $5,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,562.50 |
| Travel and Lodging | $7,583.77 |
| Food and Beverage | $5,843.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29,169.78 | 2019-2025 | Farapulse, Watchman Access System, Accolade Sr |
| Medtronic, INC. | $9,174.78 | 2021-2025 | Evera Mri Xt Dr Surescan, Affera Mapping System, Pulseselect |
| Abbott Laboratories | $5,746.86 | 2021-2025 | Aveir, Amplatzer Amulet, Ensite Precision |
| Biosense Webster, INC. | $5,132.38 | 2020-2025 | Carto 3 |
| Medtronic Vascular, INC. | $4,173.71 | 2019-2020 | |
| Aop Health US, LLC | $385.60 | 2025 | Rapiblyk |
| Atricure, INC. | $256.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.01 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $192.78 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $192.00 | 2019-2023 | Xarelto |
| Zoll Respicardia, INC. | $157.55 | 2019 | |
| Biotronik INC. | $149.24 | 2025 | Acticor 7 Vr-T Dx, Biomonitor |
| Bardy Diagnostics, INC. | $135.00 | 2020-2021 | |
| Amgen INC. | $91.34 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $86.65 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $80.01 | 2019-2022 | |
| Pfizer INC. | $78.42 | 2019-2025 | |
| Lundbeck LLC | $44.01 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.93 | 2019-2020 | |
| Ethicon US, LLC | $24.10 | 2019 | |
| Cardiva Medical, INC. | $23.82 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.22 | 2024 | |
| Novo Nordisk INC | $17.54 | 2024 | Wegovy |
| Impulse Dynamics (USA) INC. | $17.42 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $13.27 | 2021 | |
| Angiodynamics, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Winner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.